These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29781871)

  • 1. Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors.
    Thiem A; Schummer P; Ueberschaar S; Kerstan A; Kneitz H; Schrama D; Appenzeller S; Meierjohann S; Schilling B; Goebeler M; Gesierich A
    Melanoma Res; 2018 Oct; 28(5):465-468. PubMed ID: 29781871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R; Metelitsa AI; Naert KA
    Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
    Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
    Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
    Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
    Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse melanosis cutis in the setting of BRAF(V600E) mutant melanoma and treatment with targeted therapies.
    Minocha R; Kefford R; Uribe P; Sebaratnam DF; Fernández-Peñas P
    Australas J Dermatol; 2015 May; 56(2):128-30. PubMed ID: 25159853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma.
    Sebaratnam DF; Martin LK; Venugopal SS; Mangos G; Freiman J; de Souza P; Farnsworth A; Cheung K; Scolyer RA; Murrell DF
    Int J Dermatol; 2014 Nov; 53(11):1409-11. PubMed ID: 25257244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
    Cimminiello C; Indini A; Di Guardo L; Prisciandaro M; Randon G; Tolomio E; De Braud F; Del Vecchio M
    Melanoma Res; 2019 Jun; 29(3):289-294. PubMed ID: 30520799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
    Gulati N; Carvajal RD; Postow MA; Wolchok JD; Krueger JG
    Exp Dermatol; 2016 Jul; 25(7):553-4. PubMed ID: 27061281
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
    Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
    Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
    Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
    JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse melanosis cutis: a systematic review of the literature.
    Sebaratnam DF; Venugopal SS; Frew JW; McMillan JR; Finkelstein ER; Martin LK; Murrell DF
    J Am Acad Dermatol; 2013 Mar; 68(3):482-8. PubMed ID: 23219556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
    Joshi SS; Maron SB; Catenacci DV
    Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Primary central nervous system lymphoma following immunotherapy for metastatic melanoma].
    Castel M; Cotten C; Deschamps-Huvier A; Commin MH; Marguet F; Jardin F; Duval-Modeste AB; Joly P
    Ann Dermatol Venereol; 2019 Oct; 146(10):634-639. PubMed ID: 31122751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse melanosis cutis: a rare manifestation of metastatic melanoma.
    Chinai B; Piazza M; Patel R; Roy S
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31473636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report of Multiple Keratoacanthomas and Squamous Cell Carcinomas in a Patient Receiving Pembrolizumab.
    Chaudhari S; Leon A; Levin E; Neuhaus I; Liao W
    J Drugs Dermatol; 2017 May; 16(5):513-515. PubMed ID: 28628690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.